FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II
This article was originally published in The Pink Sheet Daily
Executive Summary
New unit could help better coordinate policy, operations and other biosimilar functions, FDA tells industry.
You may also be interested in...
Biosimilar Guidance Development Timelines Criticized By Docs And Patients
FDA's user fee deal with sponsors sets target dates for documents on interchangeability, naming and labeling, but non-industry stakeholders urge agency to accelerate their release; guidance development efforts will get boost in BsUFA II with funding for new dedicated biosimilars unit starting in fiscal year 2018.
Biosimilar Guidance Development Timelines Criticized By Docs And Patients
FDA's user fee deal with sponsors sets target dates for documents on interchangeability, naming and labeling, but non-industry stakeholders urge agency to accelerate their release; guidance development efforts will get boost in BsUFA II with funding for new dedicated biosimilars unit starting in fiscal year 2018.
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.